Royalty Pharma director granted 4,545 RSUs

Norden Gregory reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Norden Gregory reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Gregory Norden received a new equity grant. On June 5, 2026, he was awarded 4,545 Class A Ordinary Shares in the form of restricted stock units at a price of $0.00 per share under the company’s 2020 Independent Director Equity Incentive Plan.

The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of the next annual shareholders’ meeting, subject to plan and award terms. Following this grant, Norden directly holds 196,348 Class A Ordinary Shares.

Insider Trade Summary

Grant/Award: 4,545 shares

Grant/Award 1 txn

Insider Norden Gregory

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	4,545	$0.00	$0.00

Holdings After Transaction: Class A Ordinary Shares — 196,348 shares (Direct)

Footnotes (1)

1. F1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Key Figures

RSU grant size: 4,545 shares Grant price: $0.00 per share Post-grant holdings: 196,348 shares +2 more

5 metrics

RSU grant size 4,545 shares Restricted stock units granted on June 5, 2026

Grant price $0.00 per share Price for 4,545 Class A Ordinary Shares awarded

Post-grant holdings 196,348 shares Class A Ordinary Shares held directly after the grant

Vesting trigger 1 year or next annual meeting 100% vesting on earlier of these dates, per plan terms

Transaction date June 5, 2026 Date of RSU grant to director Gregory Norden

Key Terms

restricted stock units, 2020 Independent Director Equity Incentive Plan, vest 100%, annual meeting of the Issuer's shareholders

4 terms

restricted stock units financial

"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Independent Director Equity Incentive Plan financial

"an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan")"

vest 100% financial

"generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date"

annual meeting of the Issuer's shareholders financial

"and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Royalty Pharma (RPRX) director Gregory Norden report in this Form 4?

Gregory Norden reported receiving 4,545 Class A Ordinary Shares as a restricted stock unit award. The grant was priced at $0.00 per share and was made under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan, reflecting routine equity-based director compensation.

How many Royalty Pharma (RPRX) shares does Gregory Norden hold after this grant?

After the reported grant, Gregory Norden directly holds 196,348 Class A Ordinary Shares of Royalty Pharma. This total reflects his updated position following the 4,545-share restricted stock unit award disclosed in the Form 4 filing for the June 5, 2026 transaction date.

What are the vesting terms of Gregory Norden’s new Royalty Pharma (RPRX) restricted stock units?

The 4,545 restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of Royalty Pharma’s next annual shareholders’ meeting, subject to the terms of the 2020 Independent Director Equity Incentive Plan and the specific award agreement.

Was cash paid for the Royalty Pharma (RPRX) shares reported in this Form 4?

No cash was paid for these shares; the Form 4 lists a transaction price of $0.00 per share. The 4,545 Class A Ordinary Shares were granted as restricted stock units under Royalty Pharma’s equity incentive plan, representing non-cash, stock-based director compensation.

Is Gregory Norden’s Royalty Pharma (RPRX) transaction a purchase or an award?

The transaction is an award, not an open-market purchase. It is coded as an “A” transaction, described as a grant, award, or other acquisition, and consists of 4,545 restricted stock units granted under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan.

Which plan governs Gregory Norden’s new Royalty Pharma (RPRX) equity grant?

The award is governed by Royalty Pharma’s 2020 Independent Director Equity Incentive Plan. The Form 4 footnote explains that the 4,545 restricted stock units were granted under this plan and are subject to its terms and the applicable award agreement, including the specified vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norden Gregory

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	06/05/2026		A		4,545(1)	A	$0	196,348	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Gregory Norden	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)